/

Empresas

D&

No verificado

D&D Pharmatech, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

4 Comunicados de prensa

Ver todos los comunicados de prensa

16/06/2025

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Industria

D&D Pharmatech Announces Positive Phase 2 Results for DD01 in MASH with Robust Reductions in Liver Fat Accompanied by Improvements in Liver and Metabolic Health

Fuente

D&D Pharmatech, Inc.

Editor

1.00

0

03/02/2025

Salud

Higiene alimentaria

Medicina - Varios

Farmacéutica

Biotecnología

Industria

D&D Pharmatech Announces Completion of Patient Enrollment for a 48-Week Phase 2 Trial Evaluating the Effectiveness of DD01, a Long-Acting, Dual GLP-1/Glucagon Receptor Agonist, in the Treatment of MASH

Fuente

D&D Pharmatech, Inc.

Editor

1.00

0

21/08/2024

Higiene alimentaria

Salud

Medicina - Varios

Farmacéutica

Biotecnología

D&D Pharmatech Announces Initiation of Dosing in a Phase 2 Trial Designed to Evaluate the Efficacy and Safety of DD01, a Long-Acting, Dual GLP-1/Glucagon Receptor Agonist in Overweight/Obese Subjects with MASLD/MASH

Fuente

D&D Pharmatech, Inc.

Editor

1.00

0

02/04/2024

Accesorios de moda

Ir de compras

Medicina - Varios

D&D Pharmatech Granted Fast Track Designation from US FDA for DD01 for the Treatment of NASH/MASH

Fuente

D&D Pharmatech, Inc.

Editor

1.00

0

Seguidores

0

Compatibilidad

0